NasdaqGM:APGEBiotechs
Should Positive Phase 2 Zumilokibart Data and Blackstone Funding Reshape the Outlook for Apogee Therapeutics (APGE) Investors?
Apogee Therapeutics recently reported positive 16-week Part B Phase 2 APEX data for its anti‑IL‑13 antibody zumilokibart in moderate‑to‑severe atopic dermatitis, while also outlining an extensive late‑stage development plan across atopic dermatitis, asthma and eosinophilic esophagitis.
At the same time, Apogee entered a financing collaboration with Blackstone Life Sciences for up to US$1.30 billion in flexible, largely non‑dilutive capital tied to future zumilokibart sales, reshaping its...